Beyond Air, Inc. Common Stock (XAIR) Stock Price

XAIRStock

$4.48−89.72%52W

Market Cap$4.41M

P/E—

PEG Ratio—

Div yield—

Beta0.21

XAIR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-88.96%

Price vs S&P 500 (4W)-30.77%

VGM Score59.53

Book Value / Share (Quarterly)$10.39

P/TBV (Annual)1.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)62.09%

Cash Flow / Share (Quarterly)$-32.51

Price vs S&P 500 (YTD)-81.97%

Gross Margin (TTM)3.28%

Net Profit Margin (TTM)-432.99%

EPS (TTM)$-59.12

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-59.12

Revenue Growth (5Y)40.75%

EPS (Annual)$-80.11

ROI (Annual)-118.05%

Gross Margin (Annual)3.28%

Net Profit Margin (5Y Avg)-2190.49%

Cash / Share (Quarterly)$19.74

Revenue Growth QoQ (YoY)65.54%

ROA (Last FY)-93.96%

Revenue Growth TTM (YoY)107.26%

EBITD / Share (TTM)$-16.29

ROE (5Y Avg)-266.62%

Operating Margin (TTM)-380.38%

Cash Flow / Share (Annual)$-32.51

P/B Ratio0.88x

P/B Ratio (Quarterly)1.19x

Net Income / Employee (Annual)$-545,100

EV / Revenue (TTM)2.69x

Net Interest Coverage (TTM)-6.28x

ROA (TTM)-101.34%

EPS Incl Extra (Annual)$-80.11

Current Ratio (Annual)3.80x

Quick Ratio (Quarterly)2.83x

3-Month Avg Trading Volume0.04M

52-Week Price Return-89.72%

Revenue / Employee (TTM)$125,900

Tangible BV / Share (Quarterly)$8.66

P/S Ratio (Annual)0.70x

Asset Turnover (Annual)0.22x

52-Week High$95.60

Operating Margin (5Y Avg)-2198.85%

EPS Excl Extra (Annual)$-80.11

CapEx CAGR (5Y)2.86%

Tangible BV CAGR (5Y)-29.86%

26-Week Price Return-77.03%

Quick Ratio (Annual)2.83x

13-Week Price Return-49.66%

Total Debt / Equity (Annual)3.60x

Current Ratio (Quarterly)3.80x

Enterprise Value$20.67M

Revenue / Share Growth (5Y)173.54%

Asset Turnover (TTM)0.23x

Book Value / Share Growth (5Y)49.40%

Revenue / Employee (Annual)$125,900

Inventory Turnover (Annual)3.89x

Pretax Margin (Annual)-447.12%

Cash / Share (Annual)$19.74

3-Month Return Std Dev115.69%

Net Income / Employee (TTM)$-545,100

ROE (Last FY)-542.75%

Net Interest Coverage (Annual)-6.28x

EPS Basic Excl Extra (Annual)$-80.11

Receivables Turnover (TTM)8.55x

Total Debt / Equity (Quarterly)3.60x

EPS Incl Extra (TTM)$-59.12

ROI (TTM)-131.88%

P/S Ratio (TTM)0.70x

Pretax Margin (5Y Avg)-2275.57%

Revenue / Share (Annual)$18.50

Tangible BV / Share (Annual)$8.66

Price vs S&P 500 (52W)-108.28%

Year-to-Date Return-69.15%

5-Day Price Return-8.76%

EPS Normalized (Annual)$-80.11

ROA (5Y Avg)-95.91%

Net Profit Margin (Annual)-432.99%

Month-to-Date Return-15.07%

Cash Flow / Share (TTM)$-2.15

EBITD / Share (Annual)$-63.03

Operating Margin (Annual)-380.38%

LT Debt / Equity (Annual)3.53x

ROI (5Y Avg)-133.63%

LT Debt / Equity (Quarterly)3.53x

EPS Basic Excl Extra (TTM)$-59.12

P/TBV (Quarterly)1.42x

P/B Ratio (Annual)1.19x

Inventory Turnover (TTM)3.89x

Pretax Margin (TTM)-447.12%

Book Value / Share (Annual)$10.39

Price vs S&P 500 (13W)-51.62%

Beta0.21x

P/FCF (Annual)4.20x

Revenue / Share (TTM)$11.64

ROE (TTM)-360.45%

52-Week Low$4.25

vGradeB

gGradeA

mGradeF

vgmGradeC

XAIR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2026	Jun 26, 2026	-$11.33	-$15.40	-35.88%(-$4.07)
Q4 2025	Feb 13, 2026	-$10.80	-$17.00	-57.41%(-$6.20)
Q2 2025	Aug 12, 2025	-$26.40	-$30.60	-15.91%(-$4.20)
Q1 2025	Jun 17, 2025	-$48.80	-$36.00	+26.23%(+$12.80)
Q4 2024	Feb 10, 2025	-$64.00	-$60.00	+6.25%(+$4.00)
Q3 2024	Nov 11, 2024	-$113.60	-$112.00	+1.41%(+$1.60)

XAIR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
XAIRBeyond Air, Inc. Common Stock	B	A	F	$4.48
SYKStryker Corporation	C	B	C	$330.69
MMM3M Company	C	D	C	$174.34
BSXBoston Scientific Corp.	C	B	D	$46.84
BDXBecton, Dickinson and Co.	B	D	B	$189.52
MDLNMedline Inc. Class A common stock	C	D	C	$35.28
RMDResMed Inc.	C	B	B	$240.33
DXCMDexCom, Inc.	D	B	B	$90.82
WSTWest Pharmaceutical Services, Inc.	D	C	B	$337.47
SOLVSolventum Corporation	C	C	B	$91.12
BAXBaxter International Inc.	B	D	B	$26.13
PENPenumbra, Inc.	D	C	C	$321.68
GMEDGLOBUS MEDICAL INC	B	B	C	$82.97
GKOSGlaukos Corporation	F	A	A	$179.87
PODDInsulet Corporation	C	A	C	$145.13
TFXTeleflex Incorporated	B	F	B	$139.67
STVNStevanato Group S.p.A.	D	C	C	$21.03
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$20.10
MMSIMerit Medical Systems Inc	C	B	B	$90.49
HAEHaemonetics Corporation	C	C	A	$103.96
ICUIICU Medical Inc	C	D	B	$175.10
HTFLHeartflow, Inc. Common Stock	—	A	B	$47.78
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$120.25
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$47.57
ATRCAtriCure, Inc.	D	B	B	$48.54
UFPTUFP Technologies Inc	C	B	B	$300.05
NVCRNovoCure Limited Ordinary Shares	D	C	B	$17.82
LMATLeMaitre Vascular, Inc.	C	B	C	$80.45
INSPInspire Medical Systems, Inc.	B	B	B	$61.44
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$25.64
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.43
ATECAlphatec Holdings, Inc.	D	B	C	$9.44
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.64
IARTIntegra LifeSciences Holdings	B	D	B	$16.89
AORTArtivion, Inc.	C	C	C	$26.77
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$20.83
IRMDiRadimed Corporation	D	B	C	$87.07
BVSBioventus Inc. Class A Common Stock	B	C	A	$13.84
BBNXBeta Bionics, Inc. Common Stock	D	A	B	$19.72
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.42
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.21
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.48
MDXGMiMedx Group, Inc	C	D	C	$4.50
ANGOAngioDynamics, Inc.	C	D	A	$15.85
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$23.65
BWAYBrainsway Ltd. American Depositary Shares	F	A	B	$14.30
DCTHDelcath Systems Inc	D	B	A	$16.34
CERSCerus Corp	D	C	B	$2.65
TCMDTactile Systems Technology, Inc.	B	B	C	$23.16
NPCENeuropace, Inc. Common Stock	D	C	B	$14.41
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$15.55

About Beyond Air, Inc. Common Stock

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a proprietary nitric oxide (NO) generator and delivery system, extracting NO from ambient air for inhaled therapeutic treatment. The company is advancing its technology for pulmonary hypertension and lower respiratory tract infections.